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Summary The vaso-active drug hydralazine causes a considerable increase in the cytotoxic effect of
melphalan towards the KHT tumour in mice. The enhancement in response, measured as the concentration of
melphalan required to achieve a given tumour response, is 3.0 and 2.35 when determined using the regrowth
delay assay and the technique for determining surviving fraction in vitro following treatment in vivo
respectively. In contrast, measurement of systemic toxicity shows that the addition of hydralazine only causes
a small increase (ER= 1.15) in melphalan damage. This suggests that the drug combination may have some
therapeutic benefit. The tumour specificity for the action of hydralazine is supported by the finding that
binding of 3H-misonidazole is increased in tumours but not in other tissues when mice are treated with
hydralazine. Increased binding of labelled misonidazole is associated with an increase in the level and
duration of hypoxia, which will occur as a consequence of changes in tumour blood flow brought about by
hydralazine. However, hypoxia per se is not responsible for the enhanced effect of melphalan, since the agent
BW12C, which also induces substantial tumour hypoxia as a result of changing the 02 affinity of
haemoglobin, has no effect on melphalan tumour cytotoxicity.
There have been various reports showing that vasoactive
drugs can significantly affect the nature of blood flow in
both experimental rodent and human tumours (Algire &
Lagallais, 1951; Cater et al., 1962; Kruuv et al., 1967;
Vorhees & Babbs, 1982; Knapp et al., 1985). Reduced blood
flow in tumours can cause lowering of the oxygen status of
the tumour, thereby causing radiation resistance (Kruuv et
al., 1967). This so-called 'stealing' effect has recently been
exploited by Chaplin and Acker (1987) in order to increase
the anti-tumour effect of the bio-reductive agent, RSU 1069
(Adams et al., 1984) a compound which is activated under
hypoxic conditions to give a species 100 x more toxic than
the parent compound (Stratford et al., 1986).
Reduction of blood flow in tumours may also be poten-
tially useful for enhancing the effects of some anti-cancer
drugs. The rationale for this is that, administration of the
vaso-active drug at the time at which the chemotherapeutic
agent has reached its maximum tumour concentration, will
inhibit loss of active drug from the tumour. This could
increase the overall exposure of the tumour cells to the
cytotoxic drug. This paper describes the results of a study of
the effect of the vasoactive agent hydralazine on the cyto-
toxic action of melphalan (L-phenylalanine mustard, L-
PAM) towards the KHT sarcoma in mice.
Materials and methods
Mice and tumours
Eight to 12 week old male Category IV C3H/He mice,
obtained from NIMR, Mill Hill, London in 1984 and
subsequently bred 'in-house', were used in the present experi-
ments. The KHT sarcoma (Kallman et al., 1967), provided
by Dr P. Twentyman, MRC, Cambridge in 1983, was
maintained by inoculation of a tumour brei into the gastroc-
nemius muscle of female mice. Generally, tumours required
for experimentation were derived by subcutaneous injection
of 105 to 5 x 105 viable tumour cells (obtained by trypsin/
DNAase digestion) in the mid-dorsal pelvic region of the
back. Mice were treated when tumours attained a mean
diameter of 6-8mm.
Cell survival assay
The response of the KHT sarcoma to therapy was measured
using an in vivo to in vitro assay (Thomson & Rauth, 1974).
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Each tumour was assayed individually. Tumours were
excised 18 to 24h post-treatment, minced finely with scissors
and weighed. The tumour brei was further disaggregated by
gentle agitation for 30min with an enzyme mixture of 0.2%
trypsin and 0.05% DNAase. The resulting cell suspension
was filtered through 35pm polyester mesh, centrifuged and
the cell pellet resuspended in complete medium. Cell counts
were carried out using a haemocytometer, dilutions made
and appropriate cell numbers plated in 0.3% agar/medium
overlaid onto a 0.5% agar/medium base layer in 3cm Petri
dishes. The growth medium (Hams. F-12 plus 16.6% new-
born calf serum) was supplemented with rat red blood cells
and 2 x 104 heavily irradiated KHT cells per dish
(Courtenay, 1983). Dishes were incubated in an atmosphere
of 5% 02, 5% CO2 and 90% N2 for 14 days at 37°C.
Colonies that contained 50 or more cells were scored using a
dissecting microscope. In this series of experiments the
average cell yield for untreated tumours was 6.5 x 107 cells
per gram of tumour tissue; the drug combination, hydrala-
zine plus melphalan, did not alter the number of cells
recovered from the KHT tumours. The plating efficiency of
control cells was between 55 and 88%.
Growth delay assay
The end-point of growth delay was calculated from the time
taken for individual tumours to reach 4 x their initial
treatment volume. Mice, 6-8 per group, were treated when
tumours attained a mean diameter of about 6mm. Tumours
were measured (3 orthogonal diameters) at least 3 times
weekly.
Binding of 3H-misonidazole to tumour and normal tissues
The method of Garrecht and Chapman (1983) was used to
assess the efficiency of binding of misonidazole in hypoxic
tissue. Tritiated misonidazole (relative specific activity
236,uCi mg-1) was prepared from 1-(2-carboxy-3-methoxy
propyl)-2-nitroimidazole by reduction with tritiated sodium
borohydride (relative specific activity 5-10 Ci M - obtained
from Amersham International plc) following the procedure
of Born and Smith (1983). The product was diluted with
unlabelled misonidazole to a relative specific activity of
301Cimg-1 and each mouse in the distribution study
received 250mgkg- I i.p. of this product.
The total tritium content of weighed samples (0.05 to
0.2g) of tumour and normal tissues was measured 24h after
the injection of misonidazole, by digestion with 1.0ml of
Solusol (National Diagnostic Ltd) at 60°C for 24h. After
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digestion, 3.0ml ethanol and 15.0ml scintillant (6.5 g 1
PPO 0.5 g 1- 1 POPOP in toluene) were added and the
samples were counted on a Packard Tricarb liquid scintilla-
tion counter. A set of variably quenched standards were used
for calibration. These were prepared by adding a known
activity of tritiated water to a set of 8 samples containing
between zero and 0.2ml of whole blood digested as above.
Any very highly coloured samples were bleached by incuba-
tion at 60°C for 2h with benzoyl peroxide (0.4ml, 5% w/v
in toluene) before the addition of ethanol and scintillant.
Three groups of 5 male C3H mice bearing the KHT
tumour were injected with tritium-labelled misonidazole
(250mgkg-1). Group 1 received misonidazole only, group 2
received in i.v. injection of hydralazine (5.0mgkg-1) 15
minutes after the misonidazole and group 3 recieved 3
injections of hydralazine at 90 min intervals starting 15 min
after the misonidazole. All animals were autopsied 24h after
the injection of misonidazole and tritium analysis carried out
immediately thereafter.
Systemic toxicity
Non-tumour bearing C3H male mice were injected with
different concentrations of melphalan 15min prior to treat-
ment with hydralazine. The number of mice surviving at day
7 and day 90 were used to calculate LD50 values.
Drugs
Melphalan and BW12C were obtained from Wellcome
Research Laboratories, Beckenham, Kent. Melphalan was
dissolved in 2% acid/alcohol, diluted at least 1:10 in PBS
and injected i.p. at 0.5ml/25g mouse. BW12C was made up
in alkaline saline, adjusted to pH 7.4 by addition of HCI and
administered to mice i.v. at 0.1 ml/20g mouse. Hydralazine,
obtained from Sigma Ltd., Poole, Dorset, was dissolved in
phosphate buffered saline and injected i.v. at 0.1 ml/20g
mouse. All drug solutions were prepared immediately before
use.
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Figure 1 The effect of hydralazine (5mgkg-'), given i.v. to mice
15 min after treatment with varying doses of melphalan, on
survival of KHT tumour cells. 0, melphalan alone; 0, melpha-
lan plus hydralazine. The numbers of tumours used at each dose
level are indicated, together with the standard errors of the
pooled survival determinations.
Results
Tumour response
Data given in Figure I show the response of KHT tumour
cells taken from mice given various doses of melphalan with
or without treatment with 5mgkg-1 hydralazine 15min
later. The numbers of tumours used to determine each point
are indicated, together with standard errors of the pooled
survival determinations. It is clear that post treatment of
mice with hydralazine substantially increases the anti-tumour
effect of melphalan. The enhancement ratio (ER) is 2.35 and
is equal to the ratio of the slopes derived from regression
lines fitted through a surviving fraction of I at zero melpha-
lan dose. At a dose of 5mgkg-1 hydralazine alone has no
effect on survival of KHT tumour cells.
Figure 2 shows the effect of different doses of hydralazine
administered i.v. 15 min after treatment of mice with
6mgkg-1 melphalan. The enhancing effect of hydralazine in
decreasing cell survival reaches a maximum value over the
dose range 5-15mgkg-1. However, even at the low dose of
1 mgkg-1, hydralazine can cause a significant increase in cell
killing relative to melphalan alone, reducing the surviving
fraction from 9.6x10-2 to 3.7x10-2.
The enhancing effect of hydralazine (5mgkg 1) on
tumour cell survival is critically dependent upon the time of
administration relative to that of melphalan. This is shown
in Figure 3. Clearly, there is significant enhancement of
cytotoxicity when hydralazine is given from 90min before to
90min after melphalan. The greatest effect appearing to
occur when hydralazine is given 15min after melphalan. This
corresponds with the time at which melphalan has reached
its peak plasma levels in C3H mice (Lee & Workman, 1986).
Hydralazine causes induction of almost 100% hypoxia in
the KHT tumour and this lasts for about 90min (Stratford
et al., 1988). Experiments have been carried out to determine
to what extent the induction of hypoxia is responsible for the
observed potentiation of melphalan toxicity. This was inves-
tigated using the agent BW12C, a drug which greatly
increases tumour hypoxia by increasing the oxygen affinity
of haemoglobin (Adams et al., 1986). Experiments were
carried out to compare the effects of BW12C and hydrala-
zine in the KHT tumour. Mice were treated with a single i.v.
dose of BW12C (70mgkg-1) 15min after administration of
melphalan. The dose of BW12C induces close to 100%
tumour hypoxia within minutes after administration (Adams
et al., 1986) and the influence of this treatment on surviving
fraction of tumour cells is given in Table I. Clearly, BW12C
has no effect on the cytotoxic effect of melphalan, indicating
therefore that induction of hypoxia per se is unlikely to be
responsible for the potentiating effect of hydralazine.
Table I also shows results of experiments in which mice
were given melphalan followed 15min later by occlusion of
the tumour blood supply by a physical clamp kept in place
for 1 h. Application of a clamp alone to the tumour for this
time causes no measurable cell killing, however, when given
after melphalan, substantial cytotoxicity is observed. The
enhancement brought about by clamping is similar to that
seen with hydralazine.
Data from experiments designed to investigate any effect
of hydralazine treatment on the efficiency of any repair of
cellular damage caused by melphalan are also recorded in
Table I. Normally, tumours are excised and cell suspensions
prepared for plating in vitro 24h after treatment with drugs.
During this time repair of potentially lethal damage may
occur (see e.g. Little et al., 1973, McNally & Sheldon, 1977).
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Figure 3 The effect on tumour cell survival of giving hydrala-
zine (5 mgkg-1) i.v. to mice at varying times before or after
melphalan (6mgkg-'). Symbols + s.e. are surviving fractions
derived from separate determinations on at least three tumours.
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Figure 2 The effect of various doses of hydralazine, given i.v. to
mice 15min after treatment with 6mgkg-' melphalan, on survi-
val of KHT tumour cells. The numbers of tumours used at each
dose level are indicated, together with the standard errors of the
pooled survival determinations.
ing such a repair process, tumours from treated mice were
excised 6h after treatment and tumour cell survival com-
pared with that obtained when excision was at 24h. Results
given in Table I show that hydralazine induced enhancement
of cell killing is no different at 6h from that at 24h. This
suggests that inhibition of repair processes is unlikely to
contribute to the observed effect.
All the experiments so far described were carried out with
subcutaneous tumours. Substantial differences in blood flow
may occur in tumours implanted in alternative sites. There-
fore, the effect of hydralazine on the toxicity of melphalan
was evaluated in mice with the KHT tumour implanted into
the gastrocnemius muscle. Table I shows that, for KHT
cells implanted i.m., hydralazine also causes an increase in
cell killing, similar to that observed for the subcutaneous
tumour cells.
The effect of prolonged exposure to hydralazine was
investigated. Table II lists values of surviving fraction from
experiments where mice are adminisfered 4mgkg-1 melpha-
lan followed by a single or multiple doses of hydralazine
given at 90 min intervals. Multiple doses of hydralazine
alone have no cytotoxic effect on the KHT tumour. How-
ever, when combined with melphalan, there is an even
greater enhancement of cell kill compared to that obtained
following a single dose of hydralazine.
Growth delay of the KHT tumour has been used as an
alternative assay of response following treatment of mice
with melphalan or melphalan plus hydralazine. Growth
curves were constructed for individual tumours and the data
used to derive the time taken to reach 4 x the initial
treatment volume. Figure 4 shows mean values of growth
delay for treated tumours (T) relative to untreated controls
(Tc); plotted as a function of melphalan dose. Clearly,
hydralazine when combined with melphalan, causes an
increase in growth delay compared to that for melphalan
alone. An ER of 3.0 was derived from linear regression lines
fitted through the origin at zero melphalan dose. The value
of ER derived using the growth delay data is close to that
calculated from the results obtained by the clonogenic assay
in vitro. Treatments wth hydralazine alone has no effect on
growth of KHT tumours.
Therapeutic gain
The systemic toxicity of treatment with the drug combi-
nation was compared to that for melphalan alone. This was
Table I Anti-tumour effect of various physical and chemical treatments when given
15min after 6mgkg-1 melphalan to C3H mice carrying the KHT sarcoma
SurvivingJractiona Number of
Treatment ( x 102) tumours
Melphalan alone 9.6 (10.1-9.2) 19
Melphalan plus 5mgkg-1 hydralazine 1.0 (1.2-0.83) 11
Melphalan plus clamp for 60min 0.82 (1.3-0.53) 4
Melphalan plus BW12C 9.5 (9.8-9.2) 6
Excision at 6h:
Melphalan alone 8.5 (9.3-7.8) 6
Melphalan plus 5mgkg-1 hydralazine 1.7 (2.1-1.4) 6
Intra-muscular tumours:
Melphalan alone 17 (23-13) 4
Melphalan plus 5mgkg-1 hydralazine 1.6 (4.0-0.64) 4
aNumbers in parentheses indicate standard error limits.
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Table II Effect of hydralazine on the cytotoxic action of 4mgkg-1 melphalan towards
the KHT sarcoma
Survivingfractiona Number of
Treatment ( x 102) tumours
Melphalan alone 27 (34-22) 7
Melphalan plus 5mgkg-1 hydralazine
15min later: 3.3 (3.7-2.9) 10
As above but in addition
3 subsequent doses of 5mgkg-1
hydralazine at 90min intervals 0.47 (0.56-0.41) 5
aNumbers in parentheses indicate standard error limits.
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Figure 4 The effect of hydralazine (5mgkg-1) given i.v. to mice
15min after treatment with varying doses of melphalan on
growth of the KHT tumour. Animals were treated when tumours
attained a mean diameter of about 6mm and 6 to 8 animals were
used per group. Values of T-Tc are given+ + s.e.
Table III LD50 values for non-tumour bearing male C3H/He mice
given melphalan with or without 5mgkg-' hydralazine 15min later
Melphalan LD50/mgkg-1
Time +Hydralazine -Hydralazine ER
7 days 16.8 19.5 1.16
90 days 12.0 13.6 1.13
carried out in order to investigate whether any grounds
existed for an increase in therapeutic benefit using this
combined drug treatment. Lethal doses (LD50) were
measured at either 7 or 90 days. These times were chosen to
reflect relative toxicities in dose-limiting tissues i.e. gut and
bone marrow respectively. Table III shows that there is a
small increase in toxicity with the drug combination. How-
ever, the enhancement is substantially less than the ER
observed for the tumour response.
Binding of 3H-misonidazole
It is known that the radiosensitizer and bioreductive drug,
misonidazole, is bound in vivo to oxygen deficient tissue
(Garrecht & Chapman, 1983). Binding studies with isotopi-
cally labelled misonidazole offer an indirect method for
determining the influence of hydralazine on blood flow,
which will reflect itself as a change in oxygenation, in
various tissues. The reductive process(es) leading to binding
are inhibited by oxygen, therefore the efficiency of binding is
a measure of the degree of hypoxia (van Os-Corby &
Chapman, 1986). Mice were treated with tritiated-
misonidazole with and without hydralazine as described
previously and measurements of binding of label to various
'a
0
0
Fn
E
.0
a)
Q
u)
c
a)
a)
'a
C,)
0
E
H3
A B C A B C A B C A B C A B C
Figure 5 Binding of 3H-misonidazole to various tissues in C3H
mice bearing the KHT tumour. A, misonidazole alone; B,
misonidazole followed by hydralazine 15min later; C, as for B
but with two additional doses of hydralazine given at 90min
intervals thereafter.
Table IV Binding of 3H-misonidazole to tissues of mice bearing the
KHT sarcoma: Ratio of level of binding; MISO+hydralazine rela-
tive to MISO alone
Treatment Blood Cerebelum Spleen Liver Tumour
MISO+hydralazine 1.06 1.18 1.15 1.29 1.68a
MISO+3 x hydralazine 1.02 1.19 0.97 1.23 2.80a
Hydralazine at 5mgkg-1 given i.v. 15min post misonidazole and
at 90min intervals thereafter.
aSignificantly different from a ratio of 1.0 at P< 10-4.
mouse tissues are given in the histogram in Figure 5. In all
treatment groups, significantly greater binding of labelled
material was observed in the KHT tumour, the liver and the
spleen compared to that in blood or cerebellum. For the
group treated with misonidazole alone there is little differ-
ence between the tumour, liver and spleen. However, admi-
nistration of single or multiple doses of hydralazine increases
the amount of label in the tumour but not in any of the
other tissues (Table IV). Further, the ratios of bound,
labelled materal in tumour relative to blood give values of
1.9 in the group treated with misonidazole alone, 2.9 for the
single dose of hydralazine and 4.4 in the group receiving
three doses of hydralazine. Clearly, hydralazine substantially
increases the efficiency of misonidazole binding and this
appears to be tumour selective.
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Discussion
The major findings in this study are as follows:
1. Hydralazine substantially increases the anti-tumour
effect of melphalan in murine KHT tumours. The use
of two methods for measuring tumour response in
vivo, clonogenic assay of cell survival in vitro and
determination of tumour growth delay, both give
similar values for enhancement ratios.
2. The enhancing effect of hydralazine shows a significant
degree of tumour selectivity. The potentiation of the
antitumour effect of melphalan is not reflected by a
similar increase in either early or late systemic toxicity
of melphalan. Some tumour selectivity is also evident
in the enhancement of misonidazole-binding following
treatment with hydralazine (Table IV).
3. Hydralazine, occlusion of the blood supply and treat-
ment with BW12C all greatly increase the degree of
hypoxia in the KHT tumour. However, BW12C does
not enhance the anti-tumour action of melphalan,
strongly suggesting that the degree of tumour hypoxia
is not a factor in tumour sensitivity to melphalan.
Hydralazine is used in the treatment of acute hyperten-
sion. It acts mainly on the vascular smooth muscle causing
peripheral vaso-dilation and decreased arterial blood pres-
sure. It is known that hydralazine reduces but does not
completely occlude blood flow in some experimental tumours
(Cater et al., 1962; Kruuv et al., 1967; Vorhees & Babbs,
1982; Chan et al., 1984; Chaplin & Acker, 1987). The data in
Figure 3 show that hydralazine is effective in causing enhan-
cement even when given before treatment with melphalan.
This could be explained on the basis that hydralazine does
not prevent the access of melphalan in the tumours but
reduces the rate of tumour clearance. This would increase
therefore the overall exposure of tumour cells to melphalan.
A minor but possibly significant factor that may contribute
to the enhancing effect of hydralazine may be a reduction in
tumour pH caused by the reduced blood flow, increased
hypoxia and retention of acid products of anaerobic metabo-
lism. A small decrease in extracellular pH could increase the
stability of melphalan (Ross, 1962) thereby leading to
increased effectiveness of this drug.
Several studies have shown enhancement of the anti-
tumour effect of melphalen in vivo by a variety of agents.
Among these misonidazole, benznidazole and other nitro-
imidazoles can act as 'chemopotentiators'. The mechanism of
the effect has its basis in bioreductive activation of the nitro
compound causing damage that is only expressed when cells
are exposed to a second cytotoxic treatment (Siemann, 1984).
Changes in melphalan pharmacokinetics is also thought to
be important (Lee & Workman, 1986) as well as changes in
tumour vascular function (Murray et al., 1987). The anaes-
thetic, safan, can increase the effectiveness of melphalan in
the B16 melanoma but this is accompanied by an equivalent
increase in normal tissue toxicity (Peacock & Stephens,
1978). Similarly, the vaso-dilating agent, verapamil, also
increases the cytotoxicity of melphalan in some experimental
tumours and some normal tissues (Robinson et al., 1985). In
this latter study it was shown that the effect of verapamil is
to change melphalan pharmacokinetics and cellular uptake
rather than causing any alterations in tumour blood flow
(Robinson et al., 1985, 1986).
The evidence from the work reported here indicates that
hydralazine has a high degree of specificity in enhancing the
anti-tumour effect of melphalan. If hydralazine, or other
blood flow modifiers do not increase melphalan toxicity in
dose-limiting human normal tissues, they could have a r6le
to play in cancer chemotherapy, in addition to any use in
combination with bioreductive rad;osensitizing drugs
(Chaplin & Acker, 1987; Brown 1987; Stratford et al., 1987).
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